Quick Facts

• Up to 40% of weight lost on GLP-1 medications like Ozempic and Wegovy comes from muscle mass, not fat
• New clinical protocol combines specific protein targets, resistance training, and monitoring to preserve lean body mass
• GLP-1 prescriptions rose 587% from 2019 to 2024, with 12% of adults now using these medications

GLP-1 medications have transformed weight loss treatment, but they carry a hidden cost. Clinical studies show muscle mass accounts for up to 40% of total weight loss from these drugs.

New research from Mass General Brigham reveals a three-part protocol that prevents this muscle loss. The approach combines precise protein intake, structured resistance training, and continuous monitoring.

“As we enter a new era of obesity treatments, it’s vital to focus not just on the amount of weight lost, but on preserving muscle mass,” said Dr. Samar Hafida of the American Diabetes Association.

The protocol starts with protein targets. Patients need 1.0 to 1.5 grams of protein per kilogram of ideal body weight daily. For most adults, this equals 80 to 120 grams per day.

Protein alone fails without exercise. Clinical guidelines emphasize that increased protein intake cannot preserve muscle mass without structured resistance training.

“Current data shows combining a high protein diet and consistent exercise with GLP-1 treatment has the greatest benefit in preserving bone and muscle mass,” researchers from Mass General report.

The third component involves new biosensor technology. A 2026 study demonstrated proof of concept for continuous protein sensors that detect muscle breakdown markers in real time.

“While patients are advised to consume more protein to preserve muscle, it’s often difficult to know if they’re getting enough,” said Dr. Rebecca Gottlieb of Biolinq, who led the biosensor research.

Clinical trials also test combination therapies. Research presented in 2025 showed bimagrumab, a muscle preservation drug, enhanced semaglutide effectiveness when used together.

The muscle loss problem affects healthcare costs. Sarcopenia creates $900 in excess healthcare expenses per employee annually through falls, pain management, and additional care needs.

Three case studies demonstrate the protocol’s success. Patients with body mass indexes between 32.9 and 51.9 who followed the complete program preserved lean muscle mass during GLP-1 treatment.

The urgency grows as usage expands. GLP-1 prescriptions for adults aged 18 to 39 increased 588% from 2019 to 2024. About one in eight adults now takes these medications.

The World Health Organization added GLP-1 therapies to its Essential Medicines List in September 2025. The FDA approved the first oral GLP-1 weight loss medication, Wegovy pills, in December 2025.

Doctors emphasize starting the muscle preservation protocol immediately when beginning GLP-1 therapy. Patients who engage in regular exercise from treatment initiation show the best outcomes for maintaining lean body mass while losing fat.

Read more: The Doctor-Approved Plan for Taking a GLP-1 Without Losing Your Muscle